MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1182/blood-2011-06-363424

Медицинская библиотека · Blood · 2011

EZH2 mutational status predicts poor survival in myelofibrosis.

Guglielmelli Paola, Biamonte Flavia, Score Joannah, Hidalgo-Curtis Claire, Cervantes Francisco, Maffioli Margherita, Fanelli Tiziana, Ernst Thomas, Winkelman Nils, Jones Amy V, Zoi Katerina, Reiter Andreas, Duncombe Andrew, Villani Laura, Bosi Alberto, Barosi Giovanni, Cross Nicholas C P, Vannucchi Alessandro M

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

We genotyped 370 subjects with primary myelofibrosis (PMF) and 148 with postpolycythemia vera/postessential thrombocythemia (PPV/PET) MF for mutations of EZH2. Mutational status at diagnosis was correlated with hematologic parameters, clinical manifestations, and outcome. A total of 25 different EZH2 mutations were detected in 5.9% of PMF, 1.2% of PPV-MF, and 9.4% of PET-MF patients; most were exonic heterozygous missense changes. EZH2 mutation coexisted with JAK2V617F or ASXL1 mutation in 12 of 29 (41.4%) and 6 of 27 (22.2%) evaluated patients; TET2 and CBL mutations were found in 2 and 1 patients, respectively. EZH2-mutated PMF patients had significantly higher leukocyte counts, blast-cell counts, and larger spleens at diagnosis, and most of them (52.6%) were in the high-risk International Prognostic Score System (IPSS) category. After a median follow-up of 39 months, 128 patients (25.9%) died, 81 (63.3%) because of leukemia. Leukemia-free survival (LFS) and overall survival (OS) were significantly reduced in EZH2-mutated PMF patients (P = .028 and P < .001, respectively); no such impact was seen for PPV/PET-MF patients, possibly due to the low number of mutated cases. In multivariate analysis, survival of PMF patients was predicted by IPSS high-risk category, a < 25% JAK2V617F allele burden, and EZH2 mutation status. We conclude that EZH2 mutations are independently associated with shorter survival in patients with PMF.

Для цитирования: Guglielmelli Paola, Biamonte Flavia, Score Joannah, Hidalgo-Curtis Claire, Cervantes Francisco, Maffioli Margherita, Fanelli Tiziana, Ernst Thomas, Winkelman Nils, Jones Amy V, Zoi Katerina, Reiter Andreas, Duncombe Andrew, Villani Laura, Bosi Alberto, Barosi Giovanni, Cross Nicholas C P, Vannucchi Alessandro M. EZH2 mutational status predicts poor survival in myelofibrosis.. Blood. 2011. DOI: 10.1182/blood-2011-06-363424.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.